Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.63 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.60 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1423329 | 0.99 | CHRNB2 (0.61) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1423210 | 0.89 | ALDH1A1 (0.66) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL17220443 | 0.85 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1422846 | 0.80 | ALDH1A1 (0.74) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1423249 | 0.80 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1422890 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1421647 | 0.78 | RAB9A (0.56) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1422962 | 0.78 | CHRNB2 (0.65) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL1423193 | 0.77 | CHRNB2 (0.83) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 | |
| SCHEMBL23288103 | 0.77 | SMN1; SMN2 (0.68) | CHRNB2CHRNA5CHRNA4POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | claimed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8486979-B2 | Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009148452-A1 | NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | CHRNB2 3741/4885CHRNA5 4256/4885CHRNA4 4109/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA5 3/4885CHRNA4 1/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA5 3/4885CHRNA4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.